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OBJECTIVE — Charcot neuroarthropathy is a disabling complication of diabetes. Although
its pathogenesis remains unknown, we suppose that genetics may play a relevant role.
RESEARCH DESIGN AND METHODS — We performed a case-control study with 59
subjects with diabetic Charcot neuroarthropathy (Ch group), 41 with diabetic neuropathy
without Charcot neuroarthropathy (ND group), and 103 healthy control subjects (H group) to
evaluate the impact of two single nucleotide polymorphisms (SNPs) of the osteoprotegerin gene
(G1181C and T245G) on the risk of Charcot neuroarthropathy.
RESULTS — Regarding the SNPs of G1181C, we found a signiﬁcant linkage between the G
allele and Charcot neuroarthropathy (Ch vs. ND, odds ratio [OR] 2.32 [95% CI 1.3–4.1], P 
0.006;Chvs.H,2.10[1.3–3.3],P0.002;andNDvs.H,0.90[0.7–1.9],P0.452);similarly,
we found a linkage with the G allele of T245G (Ch vs. ND, 6.25 [2.2–19.7], P  0.001; Ch vs.
H,3.56[1.9–6.7],P0.001;andNDvs.H,0.54[0.6–5.7],P0.304),supportingaprotective
role for the allele C and T, respectively. For this reason we investigated the frequency of the
protectivedoublehomozygosisCCTT(7%inCh)thatwassigniﬁcantlylowerinChcompared
withH(0.18[0.06–0.5],P0.002)andwithND(0.17[0.05–0.58],P0.006),whereasthere
was no difference between H and ND (1.05 [0.43–2.0], P  0.468). In a multivariate logistic
backward regression model, only weight and the lack of CC and TT genotypes were indepen-
dently associated with the presence of Charcot neuroarthropathy.
CONCLUSIONS — This is the ﬁrst study that shows an association between genetic regu-
lation of bone remodeling and Charcot neuroarthropathy.
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harcot neuroarthropathy is a chronic
and progressive disease of bone and
joints, deﬁned by painful or rela-
tivelypainlessboneandjointdestruction,
in limbs that have lost sensory innerva-
tion; it is characterized by pathological
fractures,jointdislocation,anddeformity
(1). With the decline in numbers of cases
of tertiary syphilis, the primary etiology
today is diabetes. The incidence is
0.1–5% in diabetic patients with pe-
ripheral neuropathy, but it is likely that
many cases are undiagnosed (2). The ma-
jority of patients with Charcot neuroar-
thropathyarefrom50to60yearsold,and
most will have had diabetes for at least 10
years (3,4).
ThepathogenesisofCharcotneuroar-
thropathy is still unknown, but it is un-
doubtedly multifactorial (1,5); probably
this is one of the reasons that there is no
pharmacological treatment available to
stop the progress of the disease. The dif-
ference between the higher prevalence of
diabetic neuropathy and the lower preva-
lence of Charcot neuroarthropathy (neu-
ropathy seems to be necessary but not
sufﬁcient for its presence) and the differ-
ent clinical features of the two conditions
support the hypothesis of the probable
involvement of other factors in its
pathogenesis.
A common feature of Charcot neuro-
arthropathyisbonereabsorption,andthe
association between diabetes and osteo-
porosis could contribute to the presence
of Charcot neuroarthropathy (6–8). In-
deed, the study of bone turnover markers
inacuteCharcotneuroarthropathyshows
that there is an increase in osteoclast ac-
tivity compared with osteoblast activity
(9); this can lead to osteopenia, which
could predispose to fracture, even as a
consequence of minimal trauma.
New insights into the regulation of
osteoclastogenesis have resulted from the
discovery of three members of the tumor
necrosis factor (TNF) and TNF receptor
superfamily; one of these receptors, os-
teoprotegerin(OPG),isanimportantreg-
ulator of bone remodeling (10). OPG
gene single nucleotide polymorphisms
(SNPs) have been associated with osteo-
porosis (11,12) and are considered early
predictors of cardiovascular disease (13).
Two of the most studied polymorphisms
are G1181C (located in exon I) and
T245G (located in the promoter region);
the latter is in complete linkage with
A163G and G209A polymorphisms (14).
Because of their regulatory function in
bone remodeling and for their involve-
ment in the pathogenesis of osteoporosis,
wefocusedourinvestigationonthesetwo
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ciation with Charcot neuroarthropathy.
RESEARCH DESIGN AND
METHODS— The study was per-
formed in our department. We included
59 consecutive Caucasian subjects with
diabetic Charcot neuroarthropathy (Ch
group), 41 consecutive Caucasian sub-
jects with diabetic neuropathy without
Charcot neuroarthropathy (ND group),
and103healthyCaucasiansasthecontrol
subjects (H group). All diabetic subjects
had type 2 diabetes.
An assessment of vibration percep-
tion threshold was performed with a
biothesiometer, according to Young et al.
(15). All diabetic subjects had a deﬁnite
diagnosisofperipheralneuropathywitha
Neuropathy Disability Score 5 (16) and
a pathological conduction velocity. Auto-
nomicneuropathywasdiagnosedaccord-
ing to the standardized procedure of
Ewing and Clarke (17), including four
cardiovascular autonomic tests. A radio-
logical evaluation of both feet was per-
formed in all diabetic subjects (Charcot
neuroarthropathy and neuropathy only
subjects) to conﬁrm the diagnosis or the
absence of Charcot neuroarthropathy.
Clinical and radiological ﬁndings
(bonefracture,fragmentation,ordestruc-
tion and joint subluxation, dislocation, or
destruction, seen on X rays taken in two
different projections, according to the
protocol described by Cavanagh et al.
[18]) were considered as indicative of a
diagnosisofCharcotneuroarthropathy.If
the diagnosis was doubtful, magnetic res-
onanceimagingofthefeetwasperformed
(19).
This study was conducted in agree-
mentwiththeDeclarationofHelsinkiand
was approved by the ethics committee of
our hospital. All subjects provided in-
formed consent.
Restriction fragment–length
polymorphism-PCR analysis
Genomic DNA was isolated from whole
blood by standard procedures. Genotyp-
ing of the G1181C OPG exon 1 polymor-
phism was performed using a mis-
matched oligonucleotide approach. A
570-bp fragment was ampliﬁed with
primers 5-TGCGTCCGGATCTTGGCTGG-
ATCGG-3 (sense) and 5-GGGCGCGG-
CGGGCGCGCCCAGGGACTTACCACGA-
GCGCGCAGCACAGCTA-3 (antisense),
containing a T instead of an A nucleotide
two bases before the 3 end that corre-
sponds to the third base of codon 3 that
encodeslysineinexon1oftheOPGgene,
thereby introducing an artiﬁcial XspI re-
strictionsiteinthepresenceofthemutant
allele.ThePCRmixture(30l)contained
genomic DNA (100 ng), 1 PCR buffer,
0.2 mmol/l each of the four deoxyribonu-
cleotides, 1.0–2.5 mmol/l MgCl2, 0.42
mol/l each of the two oligonucleotide
primers, and 0.6 unit of AmpliTaq Gold
polymerase (Applied Biosystems, Foster
City,CA).Cyclingconditionsconsistedof
an initial 12 min at 95°C, followed by 35
cycles of 60 s at 94°C, 30 s at 56°C, and
60 s at 72°C, and ﬁnally, 7 min at 72°C.
After PCR ampliﬁcation, 5 l of each PCR
product (5 l) was digested with 3 units
XspI (Cambrex Bio Science, Apen, Ger-
many) for 16 h and subsequently ana-
lyzed on a 3% agarose gel and visualized
by ethidium bromide staining. In the
presence of a C nucleotide at position
1181, the 570-bp PCR product was
cleaved into 522- and 48-bp fragments,
respectively.
Genotyping of the T245G OPG pro-
moter polymorphism was performed by
ampliﬁcation of a 271-bp fragment with
oligonucleotide primers 5-CGA ACC
CTA GAG CAA AGT GC-3 (sense) and
5-TGT CTG ATT GGC CCT AAA GC-3
(antisense).ThePCRmixture(30l)con-
tained genomic DNA (100 ng), 1 PCR
buffer,0.2mmol/leachofthefourdeoxy-
ribonucleotides, 1.0–2.5 mmol/l MgCl2,
0.42 mol/l each of the two oligonucleo-
tide primers, and 0.6 unit of AmpliTaq
Gold polymerase (Applied Biosystems).
Cycling conditions consisted of an initial
12 min at 95°C, followed by 35 cycles of
60 s at 94°C, 30 s at 56°C, and 60 s at
72°C, and ﬁnally, 7 min at 72°C. After
PCR ampliﬁcation, 5 l of each PCR
product was digested with 3 units HinfI
restriction endonuclease (New England
Biolabs, Beverly, MA) for 16 h and subse-
quently analyzed on a 3% agarose gel and
visualized by ethidium bromide staining.
Statistical analysis
Statistical analysis was performed with
SPSS (release 15.0; SPSS, Chicago, IL).
Continuous variables are expressed as
means	SD,categoricalvariablesaredis-
played as frequencies, and the appropri-
ate parametric or nonparametric test (t
testandANOVAforcontinuousnormally
distributed variables, Mann-Whitney U
test for nonnormally distributed vari-
ables,orcorrected

2orFisher’sexacttest
forcategoricaldata)wasusedtoassessthe
signiﬁcance of the differences between
subgroups. Analysis of genotype data was
performed using PowerMarker software
(version 3.25) (20). Hardy-Weinberg
equilibrium was assessed by a 

2 test or
Fisher’s exact test as appropriate. D was
calculated to evaluate linkage disequilib-
rium for all pairwise SNP combinations.
Multivariate binary logistic analysis was
performedtoevaluatetherelationshipbe-
tweenthepresenceofCharcotdiseaseand
genotypes and clinical/laboratory ﬁnd-
ings. The coefﬁcients obtained from the
logistic regression were expressed in
terms of odds ratios (ORs) with 95% CI.
The statistical signiﬁcance was set at P 
0.05.
RESULTS— Table1showstheclinical
and laboratory characteristics of the Ch,
H, and ND groups. Comparison of OPG
polymorphisms showed signiﬁcant dif-
ferences in the frequencies of alleles be-
tween Ch versus ND and Ch versus H,
whereasNDandHwerenotdifferent(Ta-
ble 2). We found a positive association
with the G allele of G1181C in Ch com-
pared with ND and H (OR 2.32 [95% CI
1.3–4.1], P  0.006 and 2.10 [1.3–3.3],
P  0.002, respectively), whereas H and
NDwereoverlapped(0.90[0.7–1.9],P
0.452); regarding T245G, we showed a
strong positive association with the G al-
leleinChcomparedwithNDandH(6.25
[2.2–19.7], P  0.001 and 3.56 [1.9–
6.7], P  0.001, respectively), whereas
there were no differences between H and
ND (0.54 [0.6–5.7], P  0.304). Because
the frequencies of C (G1181C) and T
(T245G) alleles were lower in Ch, we an-
alyzed the distribution of the protective
double homozygosis CC  TT, which
was signiﬁcantly lower in Ch (frequency
7%) compared with that in H (0.18
[0.06–0.5], P  0.002) and ND (0.17
[0.05–0.58], P  0.006), whereas there
was no difference between H and ND
(1.05 [0.43–2.0], P  0.468). Thus, the
risk to have Charcot neuroarthropathy in
diabetic and neuropathic subjects with
CC/TThomozygosisisapproximatelysix-
fold lower (1/OR TT  CC [0.17]). In a
multivariate logistic backward regression
modelbuiltusingCharcotdiseaseasade-
pendent variable and SNPs and clinical/
laboratory values as independent
variables (Table 1), only weight and the
lack of CC and TT genotypes were inde-
pendently associated with the presence of
Charcot neuroarthropathy (1.07 [1.03–
1.12], P  0.001; 0.17 [0.04–0.71], P 
0.015; and 0.06 [0.01–0.36], P  0.002,
respectively). For example, in our popu-
lation, subjects without TT polymor-
Pitocco and Associates
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Charcot neuroarthropathy (1/OR TT
[0.06]), indicating the protective role
playedbytheallelesCandT,respectively.
Conduction velocity and amplitude,
Neuropathy Disability Score, and Auto-
nomicNeuropathyScoreweresimilarbe-
tweenChandND(Table1);moreover,no
signiﬁcantdifferencewasfoundinacom-
parison of these four variables in relation
to OPG SNPs (data not shown).
Genetic distribution of both SNPs
were in Hardy-Weinberg equilibrium.
There was a weak linkage disequilibrium
between the two SNPs (D0.330)
analyzed.
CONCLUSIONS — The difference
between the high prevalence of diabetic
neuropathy compared with the low prev-
alence of Charcot neuroarthropathy and
the different clinical features of the dis-
easesseemstosupportthehypothesisofa
not sufﬁcient role of diabetic neuropathy
in the pathogenesis of Charcot neuroar-
thropathy, with the probable involve-
ment of other factors (i.e., genetics). A
peculiar clinical trait of Charcot neuroar-
thropathyisthelowbonemineraldensity
of the foot’s bones, probably as a conse-
quence of a continuous bone resorption
linked to unbalanced osteoclast/
osteoblast activity; in this balance the re-
ceptor activator for NF-B (RANK)-
RANK ligand (RANKL) system and its
decoy receptor OPG play a pivotal role.
Genes of the OPG/RANKL/RANK axis
and their polymorphisms, which have al-
ready been involved in the pathogenesis
ofosteoporosis,mightbeidentiﬁedasim-
portant mediators for paracrine signaling
in bone metabolism of Charcot neuroar-
thropathy. This is the ﬁrst study that has
investigated the possible relationship be-
tween genetics and Charcot neuroar-
thropathy, demonstrating a strong
association between OPG G1181C and
T245G polymorphisms, located in the
exon 1 region and promoter region, re-
spectively, and Charcot neuroarthropa-
thy. The signiﬁcant association between
OPG SNPs and Charcot neuroarthropa-
thy (comparing Ch with ND groups) con-
ﬁrmed that SNPs are an additional risk
factor, besides diabetes and neuropathy,
for the presence of Charcot disease. Vari-
ations in exon 1 of the OPG gene could
result in a qualitative alteration of OPG
synthesis,thuscompromisingitsfunction
as a decoy receptor, whereas variations in
the sequence of the promoter region of
theOPGgenecouldresultinalteredbind-
ing of different transcription factors, thus
affecting the expression of OPG (quanti-
tative alteration) and consequently the
OPG/RANKL ratio.
Furthermore, we should envision
Charcot neuroarthropathy as a microen-
vironment characterized by a persistent
inﬂammation, linked to a probable neu-
ropathic dysregulation of the inﬂamma-
tion (“inﬂammatory reﬂex”) (21), with an
increased level of cytokines such as
TNF-, interleukin-1
, and interleu-
kin-6thatcanpromoteosteoclastogenesis
in synergy with RANKL, exceeding the
protective capacity of OPG (22). From
this point of view, both genetics and per-
sistent inﬂammation might compromise
the balanced process of bone remodeling
and be involved in the pathogenesis of
osteolyticbonedisorders.Finally,therole
of overweight (conﬁrmed by our meta-
analysis data) could be double: mechani-
cal (constant weight bearing on the foot)
(23) and metabolic (“metabolic inﬂam-
mation” of obesity) (24).
In summary, our results support the
hypothesis that Charcot neuroarthropa-
thy is a disease in which genetics plays an
essential role.
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